The cytotoxic potential of human newborn hematopoietic mononuclear cells are decreased when compared with older infant or adult cells. These defects may be responsible for impaired killing of certain bacteria and viruses and for increased neonatal morbidity and mortality. Cytotoxic deficiencies that have been described include ADCC (I), NK cytotoxicity (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , and several forms of T cell cytotoxicity including lectin-dependent cytotoxicity and specific viral-induced CTL (1 3-1 7). A newly recognized form of nonspecific cytotoxicity induced by incubation of mononuclear cells with (IL-2), termed LAK cell cytotoxicity, has been described (18) . Recently, cord LAK cell activity was demonstrated to be equally as cytotoxic against similar in vitro targets as adult LAK cells (19) . These observations suggest the possible application and investigation of the LAK phenomenon to be used as an adjuvant treatment for neonatal viral infections and pediatric neoplasms.
Therapy with LAK cells offers a new approach in the treatment of cancer. Phase I and I1 trials with IL-2 in very advanced neoplastic diseases in adults have been shown to produce encouraging therapeutic results (20, 2 1). These studies were based upon in vifro studies demonstrating that cells from fresh tumors such as melanoma, sarcomas, or ovarian carcinomas can be lysed by LAK cells (22) . In addition, adoptive transfer of such cells (LAK) and IL-2 were effective in vivo in a variety of murine tumors, including the B 16 and M3 melanomas, the MCA-10 1, 105, and 106 syngeneic sarcomas, the 1660 murine bladder carcinoma, and the MC-38 murine colon adenocarcinoma (23) (24) (25) . The relevance of these in vifro and in vivo studies in pediatric malignancies still remains to be determined. At the present time, phase I studies are just currently underway at the National Cancer Institute/Pediatric Oncology Branch and collaborative Children's Cancer Study Group institutions to investigate the administration of continuous infusion IL-2 to children with relapsed pediatric solid tumors (Sondal P, personal communication).
In view of the possibility of using adoptive adjuvant immunotherapy of cytotoxic cells (LAK) to treat pediatric cancer patients, the use of target cells from pediatric relevant tumors or continuous cell lines was therefore investigated in this study. We examined LAK cell activity toward continuous cell lines derived from neural crest tumors, Wilms' tumor, Ewing's sarcoma, and rhabdomyosarcoma as well as the standard NK-resistant but LAK-sensitive Daudi or Raji cell lines. We found that all of these cell lines were susceptible to cord and adult LAK cell activity.
MATERIALS AND METHODS
Cell lines. The LAK cell generation. Heparinized venous cord blood (n = 10) was drawn by direct venipuncture of a placental vessel after placental delivery following normal term pregnancies. Normal adult samples (n = 12) were drawn from consenting healthy adult volunteers. Red blood cells were allowed to sediment after the addition of 6% Dextran-70 in 0.9% saline (Travenol, Deerfield, IL). The leukocyte-enriched plasma was layered on a FicollHypaque gradient (Sigma Chemical Co., St. Louis, MO) (d = 1.077) and centrifuged for 30 min. Mononuclear cells were recovered from the Ficoll interface and washed twice with PBS. Cells were resuspended in RPMI 1640 medium (Flow Laboratories) supplemented with 10% heat-inactivated, pooled human AB serum, (GIBCG, Grand Island, NY) with 100 mg/ml penicillin, 100 mg/ml streptomycin, and 2 mM glutamine.
Mononuclear cells prepared from cord blood and adult peripheral blood were centrifuged and resuspended in RPMI 1640 supplemented with 10% AB serum for testing for cytotoxicity. The differential of mononuclear cells in cord blood was 69% lymphocytes and 20% monocytes compared to 65% lymphocytes and 20% monocytes in the mononuclear population of adult blood. Previous titrations indicated that incubation of lymphocytes with 100 U/ml of IL-2 resulted in peak cytotoxic activity toward Raji and Daudi target cells (19) . Previous work also established that minimal NK activity remained after 5-7 days' incubation without the presence of IL-2 (19) . Therefore, whole mononuclear cells were incubated with or without IL-2 (Cetus Corp., Emeryville, CA) (100 U/ml) for 5-7 days at a cell concentration of 1 x lo6 cells/ml in RPMI 1640 supplemented as described above. At the end of the incubation, they were centrifuged, and the cell pellet was adjusted to 4 X lo6 cells/ml in fresh RPMI 1640 with 10% AB serum.
Cytotoxicity assay. Target cells were labeled with 51Cr and adjusted to a cell concentration of 1 X lo5 cells/ml. Aliquots of 0.1 ml were then placed in a 96-well round-bottom microtiter plate, and effector mononuclear cells were then added to each well at an effector-to-target cell ratio of 40: 1 (19, 26) . After a 4-h incubation, aliquot samples were counted in a scintillation counter (Beckman Instruments, Inc., Fullerton, CA Figure 1 as the activity toward the K562 (NK sensitive) and Raji (NK resistant but LAK sensitive) cell lines. Cord cells tend to show higher cytotoxicity toward the K562 cell line than cells from similarly treated adult peripheral blood. A similar trend was also observed with the Raji targets. Similar levels of activity were also seen against another NKresistant cell line, Daudi (results not shown).
There was a significant increase in cord LAK activity demonstrated toward the SH-SY5Y neuroblastoma cell line compared with adult LAK activity ( p 5 0.01). There was, however, no significant different between cord and adult LAK cytotoxic activity in the other neural crest-derived cell line, SK-NM-C (Fig.   A) .
LAK activity against the other pediatric solid tumors, Wilms', Ewing's sarcoma, and rhabdomyosarcoma is shown in Figure 3 . High levels of LAK cytotoxicity are present towards both Wilms' tumor (SK-NEP-I), and Ewing's sarcoma (SK-ES-I) respectively. Of all the pediatric tumor cell lines tested, rhabdomyosarcoma (A-204) appears to be least affected by either cord or adult LAK cells (Fig. 3) .
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There was only 5% or less specific cell lysis seen in the cytotoxic assays in both cord and adult samples incubated without IL-2 against K-562, Raji and the other five pediatric tumor cell lines (data not shown). Specifically, LAK cell activity is characterized by its ability to lyse cell lines resistant to killing by NK cells. Commonly, EBVtransformed cell lines (such as Raji or Daudi) or melanoma cell lines have been used as target cells which are derived from tumors of little relevance to pediatric oncology. Although the phenomenon of LAK cell activity has been studied extensively in both normal adults and adults with cancer (21), it has not been well documented and studied in younger populations except in two abstracts. Atzpodien et al. (27) recently presented evidence of adult LAK cytotoxic activity towards three neuroblastoma cell lines, SMS-SAN, SK-N-BE2, and LA-N-1 but did not study neonatal or pediatric LAK activity. Sabio et al. (28) demonstrated pediatric LAK cytotoxic activity from five children with neuroblastoma and two children with Wilms' tumor against standard adult LAK-sensitive cell lines of human melanoma, FEMX.
We have chosen to study the susceptibility of five continuous cell lines derived from pediatric tumors. SK-NM-C is a neuroblastoma cell line which produces neuroblastoma in nude mice as well as in the hamster cheek. The cells were initially isolated from a retroorbital tumor in 14-y-old girl (29) . This cell line is probably a PNET cell line similar to a neuroepithelioma. In contrast, SH-SYSY cells were subcloned from a cell line derived from bone marrow in a 4-y-old patient with disseminated neuroblastoma (29) . SK-NEP-1 was isolated from a malignant pleural effusion of a patient with Wilms' tumor in 1971 (30) This study demonstrates that all of these pediatric tumor cell lines are sensitive to both adult and cord LAK cytotoxic activity. The classical neuroblastoma cell line appears to be most susceptible to neonatal mononuclear LAK activity, compared to that of adult LAK activity. It is possible that the two neuroblastoma cell lines may differ in the extent of their oncogene expression. Lanza et al. (32) has recently shown that oncogene-transfected tumor cells are susceptible to lysis by NK and LAK cells. Indeed, oncogene induction results in enhanced lytic susceptibility (33) . Inasmuch as the prognosis in neuroblastoma has also been related to N-myc expression, SH-SY5Y cells may have increased oncogene expression resulting in enhanced LAK killing. Indeed, expression of N-and C-myc oncogenes have been shown for neuroblastoma subclones (specifically SH-SY5Y) but not in other sublines of the parent SK-N-SH cell line (34) . Other differences between the two cell lines have been found, however. SK-N-SH has been determined to contain high dopamine-hydroxylase activity, whereas SK-N-MC has no detectable activity. SK-N-MC cells, but not SK-N-SH, showed intracellular catecholamine immunofluorescence. However, growth and biochemical data do confirm that the two lines represent mzlignant cells of neurogenic origin (35) .
The differential killing between cord and adult cells also suggests a host role as well. The survival for advanced congenital stage IV S neuroblastoma is 70-90% without adjuvant chemotherapy or radiation therapy (36) . However, the survival rate, for stage IV neuroblastoma, another form of advanced neuroblastoma, appears to be age related: infants older than I y have a poor prognosis with survival rates less than 20% (37). Our study revealed increased LAK cytotoxicity in cord versus adult mononuclear cells against SH-SY5Y (5 1.2 a 6.9 versus 28.5 a 8.2%) (p 5 0.01). These results suggest a possible cellular immune mechanism for the improved prognosis for advanced neuroblastoma diagnosed in the newborn versus those derived in older patients.
This study also demonstrated high levels of LAK cytoxicity for both cord and adult mononuclear cells against both the Wilms' and Ewing's sarcoma cell lines. Additionally, it may be clinically significant that the rhabdomyosarcoma cell line (A-204) was the least susceptible to LAK lysis. Whether patients with rhabdomysarcoma will be less responsible to LAK immunotherapy remains to be determined. Based on our in vitro results described above, neuroblastoma, Wilms', and Ewing's sarcoma could be good candidates for LAK and/or IL-2 adoptive immunotherapy. It is important to recognize, however, that a limited panel of cell lines was examined and that using more cell lines of each tumor type will strengthen these initial observations. In addition, only cord blood LAK activity was examined in this original study. Studies are currently in progress to determine whether mononuclear cells from children of differing ages can be activated in vitro by IL-2 to generate highly cytotoxic LAK cells against other neuroblastoma cells (such as N-myc amplified cell lines).
